EPIX - ESSAファ―マ （ESSA Pharma Inc.）EPIXのニュース
ESSA Pharma Inc. (EPIX) deserves closer scrutiny 2022/11/24 13:32:00 US Post News
ESSA Pharma Inc. (NASDAQ:EPIX) marked $3.11 per share on Wednesday, down from a previous closing price of $3.19. While ESSA Pharma Inc. has underperformed by -2.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EPIX fell by -76.24%, with highs and lows ranging from $14.88 to […]
How did ESSA Pharma Inc. (EPIX) fare last session? 2022/11/16 12:48:00 US Post News
As of Tuesday, ESSA Pharma Inc.’s (NASDAQ:EPIX) stock closed at $3.98, up from $3.38 the previous day. While ESSA Pharma Inc. has overperformed by 17.75%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EPIX fell by -69.36%, with highs and lows ranging from $14.88 to $1.40, […]
ESSA Pharma: Combination Shows Efficacy In Prostate Cancer (TSXV:EPI:CA) 2022/11/16 03:01:32 Seeking Alpha
ESSA has been in the investor spotlight after the recently presented data for its product candidate EPI-7386 with Xtandi. Read why EPIX stock is a Buy.
Fantasy Injury Updates: Latest news on Cordarrelle Patterson, James Conner, D''Andre Swift more RBs impacting Week 9 start ''em, sit ''em calls 2022/11/06 16:33:00 Kwhen Finance
ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials 2022/10/31 15:13:22 Benzinga
ESSA Pharma Inc (NASDAQ: EPIX ) announced that Johnson & Johnson''s (NYSE: JNJ ) Janssen is suspending enrollment into the Phase 1 study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients due to operational challenges. Before suspending enrollment, Janssen treated three mCRPC patients (pre-chemotherapy) with the combination of … Full story available on Benzinga.com
Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) 2022/08/06 19:00:00 Stocks Register
ESSA Pharma Inc. (NASDAQ:EPIX) shares, rose in value on Friday, 08/05/22, with the stock price down by -0.66% to the previous day’s close as strong demand from buyers drove the stock to $3.00. Actively observing the price movement in the last trading, the stock closed the session at $3.02, falling within a range of $2.95 … Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) Read More »
ESSA Pharma GAAP EPS of -$0.20 2022/08/04 12:47:00 Seeking Alpha
ESSA Pharma press release (EPIX): FQ3 GAAP EPS of -$0.20 (vs
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 2022/08/04 11:00:00 PR Newswire
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate…
Essa Pharma trades 6% higher after 10% owner buys more shares 2022/07/21 16:05:48 Seeking Alpha
Essa Pharma (EPIX) is trading 6% higher after its 10% owner Growth Biotech bought 300,000 common shares at $3.1558 for $947K.Growth Biotech now owns 5,879,583 common shares.
EPIX Stock Gains 11.6% on Insider Buys 2022/07/21 14:50:05 TipRanks
Shares of ESSA Pharma (NASDAQ: EPIX) have tanked 22% in the past month, while the short interest in the stock stood at 4.5%. However, shares have been on an upswing in the past five days, going up by 11.6% following corporate insiders'' buying of the stock. EPIX is a clinical-stage pharmaceutical company that develops novel therapies for the treatment of prostate cancer. The pharma company has seen an uptick in insider interest with BB Biotech AG, holding a more than 10% stake in EPIX, loading up on its shares. BB Biotech bought shares worth $945,000 on July 20 and $1.7 million on July 18, respectively.
Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) 2022/08/06 19:00:00 Stocks Register
ESSA Pharma Inc. (NASDAQ:EPIX) shares, rose in value on Friday, 08/05/22, with the stock price down by -0.66% to the previous day’s close as strong demand from buyers drove the stock to $3.00. Actively observing the price movement in the last trading, the stock closed the session at $3.02, falling within a range of $2.95 … Things To Consider Before Buying ESSA Pharma Inc. (NASDAQ: EPIX) Read More »
ESSA Pharma GAAP EPS of -$0.20 2022/08/04 12:47:00 Seeking Alpha
ESSA Pharma press release (EPIX): FQ3 GAAP EPS of -$0.20 (vs
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 2022/08/04 11:00:00 PR Newswire
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate…
Essa Pharma trades 6% higher after 10% owner buys more shares 2022/07/21 16:05:48 Seeking Alpha
Essa Pharma (EPIX) is trading 6% higher after its 10% owner Growth Biotech bought 300,000 common shares at $3.1558 for $947K.Growth Biotech now owns 5,879,583 common shares.
EPIX Stock Gains 11.6% on Insider Buys 2022/07/21 14:50:05 TipRanks
Shares of ESSA Pharma (NASDAQ: EPIX) have tanked 22% in the past month, while the short interest in the stock stood at 4.5%. However, shares have been on an upswing in the past five days, going up by 11.6% following corporate insiders'' buying of the stock. EPIX is a clinical-stage pharmaceutical company that develops novel therapies for the treatment of prostate cancer. The pharma company has seen an uptick in insider interest with BB Biotech AG, holding a more than 10% stake in EPIX, loading up on its shares. BB Biotech bought shares worth $945,000 on July 20 and $1.7 million on July 18, respectively.